Last articles

Dalfampridine, Ampyra*, to improve walking difficulties in patients with multiple sclerosis

Author : Pierre Allain Date : 2010-1-30

The FDA (January 2010) approved Ampyra*, dalfampridine, for improving walking in patients with multiple sclerosis.

Dalfampridine is another name of fampridine or 4-aminopyridine already introduced in Pharmacorama.

Ampyra* is a slow-release preparation. The dosage recommended is 10 mg twice daily. An overdose can cause seizures.

Your turn
User session
Bookmark, share this page
Bookmark and Share

© 2000-2019 CdM Editions / P. Allain. All rights reserved
Pharmacorama Charter